PL1805170T3 - Inhibitory MIF - Google Patents
Inhibitory MIFInfo
- Publication number
- PL1805170T3 PL1805170T3 PL05798257T PL05798257T PL1805170T3 PL 1805170 T3 PL1805170 T3 PL 1805170T3 PL 05798257 T PL05798257 T PL 05798257T PL 05798257 T PL05798257 T PL 05798257T PL 1805170 T3 PL1805170 T3 PL 1805170T3
- Authority
- PL
- Poland
- Prior art keywords
- sub
- mif
- inhibitors
- cycloalkyl
- aryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- OOYREISBUILOLV-UHFFFAOYSA-N 3,4-dihydro-1,3-benzoxazin-2-one Chemical class C1=CC=C2OC(=O)NCC2=C1 OOYREISBUILOLV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0423405.0A GB0423405D0 (en) | 2004-10-21 | 2004-10-21 | Organic compounds |
| PCT/EP2005/011233 WO2006045505A1 (en) | 2004-10-21 | 2005-10-19 | Mif-inhibitors |
| EP05798257A EP1805170B1 (en) | 2004-10-21 | 2005-10-19 | Mif-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1805170T3 true PL1805170T3 (pl) | 2010-09-30 |
Family
ID=33484961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05798257T PL1805170T3 (pl) | 2004-10-21 | 2005-10-19 | Inhibitory MIF |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7378416B2 (pl) |
| EP (1) | EP1805170B1 (pl) |
| JP (1) | JP2008517020A (pl) |
| KR (1) | KR100875767B1 (pl) |
| CN (1) | CN101035782A (pl) |
| AT (1) | ATE464307T1 (pl) |
| AU (1) | AU2005298923B2 (pl) |
| BR (1) | BRPI0516981A (pl) |
| CA (1) | CA2581981A1 (pl) |
| DE (1) | DE602005020666D1 (pl) |
| ES (1) | ES2344655T3 (pl) |
| GB (1) | GB0423405D0 (pl) |
| MX (1) | MX2007004738A (pl) |
| PL (1) | PL1805170T3 (pl) |
| PT (1) | PT1805170E (pl) |
| RU (1) | RU2383541C2 (pl) |
| WO (1) | WO2006045505A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0507695D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| ES2412858T3 (es) | 2005-09-26 | 2013-07-12 | Avigen, Inc. | Procedimiento para tratar adicciones a drogas y conductuales |
| CA2653345A1 (en) | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| WO2007142923A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Mif inhibitors for treating neuropathic pain and associated syndromes |
| CN102186833A (zh) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | Mif调节剂 |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| EP2198879A1 (en) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell |
| WO2014200872A1 (en) | 2013-06-09 | 2014-12-18 | Rjs Biologics Llc | Pharmaceutical compounds targeted by mif affinity-tethered moieties |
| WO2015095052A1 (en) | 2013-12-17 | 2015-06-25 | Controlled Chemicals, Inc. | Isoindolin-1-ones as macrophage migration inhibitory factor (mif) inhibitors |
| EP2944310B1 (en) | 2014-05-16 | 2018-03-21 | Mifcare | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension |
| US10899739B2 (en) | 2017-11-15 | 2021-01-26 | Yale University | Macrophage migration inhibitory factor inhibitors, and methods of making and using same |
| WO2019178480A1 (en) | 2018-03-15 | 2019-09-19 | Yale University | Pyrazole-containing macrophage migration inhibitory factor inhibitors |
| CA3134765A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| BR112021012113A2 (pt) | 2018-12-19 | 2021-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Moléculas bifuncionais para direcionamento lisossomal e composições e métodos relacionados |
| EP4232027A1 (en) * | 2020-10-26 | 2023-08-30 | Yale University | Macrophage migration inhibitory factor inhibitors, and methods of making and using same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6081182A (ja) * | 1983-10-12 | 1985-05-09 | Kissei Pharmaceut Co Ltd | チオフエン誘導体及びその製造方法 |
| JP4403305B2 (ja) * | 2001-09-03 | 2010-01-27 | 武田薬品工業株式会社 | １，３−ベンゾチアジノン誘導体および用途 |
| GB0507695D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
-
2004
- 2004-10-21 GB GBGB0423405.0A patent/GB0423405D0/en not_active Ceased
-
2005
- 2005-10-19 ES ES05798257T patent/ES2344655T3/es active Active
- 2005-10-19 EP EP05798257A patent/EP1805170B1/en not_active Not-in-force
- 2005-10-19 CA CA002581981A patent/CA2581981A1/en not_active Abandoned
- 2005-10-19 WO PCT/EP2005/011233 patent/WO2006045505A1/en active Application Filing
- 2005-10-19 AU AU2005298923A patent/AU2005298923B2/en not_active Expired - Fee Related
- 2005-10-19 RU RU2007118727/04A patent/RU2383541C2/ru not_active IP Right Cessation
- 2005-10-19 KR KR1020077008985A patent/KR100875767B1/ko not_active IP Right Cessation
- 2005-10-19 PL PL05798257T patent/PL1805170T3/pl unknown
- 2005-10-19 CN CNA2005800342065A patent/CN101035782A/zh active Pending
- 2005-10-19 DE DE602005020666T patent/DE602005020666D1/de active Active
- 2005-10-19 BR BRPI0516981-0A patent/BRPI0516981A/pt not_active IP Right Cessation
- 2005-10-19 JP JP2007537198A patent/JP2008517020A/ja active Pending
- 2005-10-19 AT AT05798257T patent/ATE464307T1/de active
- 2005-10-19 US US11/576,610 patent/US7378416B2/en not_active Expired - Fee Related
- 2005-10-19 MX MX2007004738A patent/MX2007004738A/es active IP Right Grant
- 2005-10-19 PT PT05798257T patent/PT1805170E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2581981A1 (en) | 2006-05-04 |
| BRPI0516981A (pt) | 2008-09-30 |
| JP2008517020A (ja) | 2008-05-22 |
| KR100875767B1 (ko) | 2008-12-26 |
| ATE464307T1 (de) | 2010-04-15 |
| CN101035782A (zh) | 2007-09-12 |
| AU2005298923A1 (en) | 2006-05-04 |
| WO2006045505A1 (en) | 2006-05-04 |
| AU2005298923B2 (en) | 2009-12-17 |
| ES2344655T3 (es) | 2010-09-02 |
| PT1805170E (pt) | 2010-07-12 |
| US20070219189A1 (en) | 2007-09-20 |
| US7378416B2 (en) | 2008-05-27 |
| EP1805170B1 (en) | 2010-04-14 |
| MX2007004738A (es) | 2007-06-18 |
| RU2383541C2 (ru) | 2010-03-10 |
| EP1805170A1 (en) | 2007-07-11 |
| DE602005020666D1 (en) | 2010-05-27 |
| KR20070054253A (ko) | 2007-05-28 |
| GB0423405D0 (en) | 2004-11-24 |
| RU2007118727A (ru) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005020666D1 (en) | Mif-hemmer | |
| ATE482932T1 (de) | N-alkynyl-2-(substituierte aryloxy)alkylthioamide derivate als fungizide | |
| ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
| AP2005003366A0 (en) | Pyrimidine derivatives for the prevention of HIV infection. | |
| DE602004006169D1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate | |
| ATE516291T1 (de) | Thenopyrimidin-verbindungen mit fungizider aktivität | |
| DE602004007730D1 (de) | Niedrig gekohlter Automatenstahl. | |
| WO2007062308A3 (en) | Homo- and heterocyclic compounds suitable as cetp inhibitors | |
| DE602004024770D1 (de) | Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
| DK1963295T3 (da) | 3,6-dihydro-2-oxo-6H-(1,3,4)thiazinderivater | |
| IS8042A (is) | Benz[1,2,5]thíadíazól efnasambönd | |
| NL1030010A1 (nl) | 4-Amino-gesubstitueerde-2-gesubstitueerde-1,2,3,4- tetrahydrochinolineverbindingen. | |
| IL185997A0 (en) | Substituted aryl 1.4-pyrazine derivatives background of the invention | |
| GB2441923A (en) | A clamp arrangement for use with doors | |
| ITMI20030485A1 (it) | Rilevatore di sfasamento perfezionato, particolarmente | |
| UA97237C2 (ru) | Производные таксола с противоопухолевой активностью | |
| ES1055317Y (es) | Escenario autotransportable. | |
| ES1058990Y (es) | Cajon. | |
| ITTO20030435A1 (it) | Automotore overhead combinato. | |
| ITTO20010601A1 (it) | Zaino per anti scogliosi. | |
| PL370543A1 (pl) | Całorzędowy, zaczepiany do ciągnika, kombajn do zbioru owoców jagodowych, zwłaszcza malin | |
| ES1052333Y (es) | Cajon premarco. | |
| IS8330A (is) | 2-Metoxýmetýl-3-(3,4-díklórófenýl)-8-asabísýkló[3.2.1]oktan-tartrasölt | |
| RU2004122005A (ru) | 2-амино-4-ацетилтиазоло[5,4-b]индол, защищающий печень от отравления четыреххлористым углеродом | |
| ITBO20030038A1 (it) | Conglomerato, particolarmente per la realizzazione |